CERS
Price
$1.39
Change
+$0.03 (+2.21%)
Updated
Jul 25 closing price
Capitalization
342.62M
9 days until earnings call
STRR
Price
$2.10
Change
-$0.05 (-2.33%)
Updated
Jul 25 closing price
Capitalization
14.07M
Interact to see
Advertisement

CERS vs STRR

Header iconCERS vs STRR Comparison
Open Charts CERS vs STRRBanner chart's image
Cerus
Price$1.39
Change+$0.03 (+2.21%)
Volume$531.44K
Capitalization342.62M
Star Equity Holdings
Price$2.10
Change-$0.05 (-2.33%)
Volume$35.76K
Capitalization14.07M
CERS vs STRR Comparison Chart in %
Loading...
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STRR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CERS vs. STRR commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERS is a Hold and STRR is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (CERS: $1.39 vs. STRR: $2.10)
Brand notoriety: CERS and STRR are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CERS: 46% vs. STRR: 115%
Market capitalization -- CERS: $342.62M vs. STRR: $14.07M
CERS [@Medical Specialties] is valued at $342.62M. STRR’s [@Medical Specialties] market capitalization is $14.07M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CERS’s FA Score shows that 0 FA rating(s) are green whileSTRR’s FA Score has 1 green FA rating(s).

  • CERS’s FA Score: 0 green, 5 red.
  • STRR’s FA Score: 1 green, 4 red.
According to our system of comparison, both CERS and STRR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CERS’s TA Score shows that 4 TA indicator(s) are bullish while STRR’s TA Score has 4 bullish TA indicator(s).

  • CERS’s TA Score: 4 bullish, 4 bearish.
  • STRR’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CERS is a better buy in the short-term than STRR.

Price Growth

CERS (@Medical Specialties) experienced а +2.21% price change this week, while STRR (@Medical Specialties) price change was +5.79% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +3.01%. For the same industry, the average monthly price growth was +4.92%, and the average quarterly price growth was -2.24%.

Reported Earning Dates

CERS is expected to report earnings on Oct 30, 2025.

STRR is expected to report earnings on May 14, 2025.

Industries' Descriptions

@Medical Specialties (+3.01% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CERS($343M) has a higher market cap than STRR($14.1M). STRR YTD gains are higher at: -7.080 vs. CERS (-9.740). STRR has higher annual earnings (EBITDA): -1.69M vs. CERS (-26.34M). CERS has more cash in the bank: 65.9M vs. STRR (23.2M). STRR has less debt than CERS: STRR (3.61M) vs CERS (96M). CERS has higher revenues than STRR: CERS (156M) vs STRR (45.8M).
CERSSTRRCERS / STRR
Capitalization343M14.1M2,433%
EBITDA-26.34M-1.69M1,561%
Gain YTD-9.740-7.080138%
P/E RatioN/AN/A-
Revenue156M45.8M341%
Total Cash65.9M23.2M284%
Total Debt96M3.61M2,660%
FUNDAMENTALS RATINGS
CERS vs STRR: Fundamental Ratings
CERS
STRR
OUTLOOK RATING
1..100
244
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
98
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9696
PRICE GROWTH RATING
1..100
6460
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CERS's Valuation (43) in the Medical Specialties industry is somewhat better than the same rating for STRR (98). This means that CERS’s stock grew somewhat faster than STRR’s over the last 12 months.

CERS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as STRR (100). This means that CERS’s stock grew similarly to STRR’s over the last 12 months.

CERS's SMR Rating (96) in the Medical Specialties industry is in the same range as STRR (96). This means that CERS’s stock grew similarly to STRR’s over the last 12 months.

STRR's Price Growth Rating (60) in the Medical Specialties industry is in the same range as CERS (64). This means that STRR’s stock grew similarly to CERS’s over the last 12 months.

STRR's P/E Growth Rating (1) in the Medical Specialties industry is significantly better than the same rating for CERS (100). This means that STRR’s stock grew significantly faster than CERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CERSSTRR
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
78%
Declines
ODDS (%)
Bearish Trend 9 days ago
84%
Bearish Trend 25 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STRR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ILIKF0.610.01
+0.83%
Ilika PLC.
SKSUY85.79N/A
N/A
Sekisui Chemical Co.
CSPHF0.62N/A
N/A
CSTONE PHARMACEUTICALS
APRAF0.24-0.01
-3.33%
Trailbreaker Resources Ltd.
NAUBF24.58-1.11
-4.32%
National Australia Bank Ltd. (Victoria, Australia)

CERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CERS has been loosely correlated with LAB. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then LAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERS
1D Price
Change %
CERS100%
+2.21%
LAB - CERS
52%
Loosely correlated
-4.76%
NNOX - CERS
47%
Loosely correlated
N/A
UTMD - CERS
46%
Loosely correlated
N/A
ICUI - CERS
46%
Loosely correlated
+0.55%
BLFS - CERS
45%
Loosely correlated
+1.44%
More

STRR and

Correlation & Price change

A.I.dvisor indicates that over the last year, STRR has been closely correlated with CATX. These tickers have moved in lockstep 88% of the time. This A.I.-generated data suggests there is a high statistical probability that if STRR jumps, then CATX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STRR
1D Price
Change %
STRR100%
-2.33%
CATX - STRR
88%
Closely correlated
-2.17%
NSYS - STRR
29%
Poorly correlated
-0.93%
CERS - STRR
23%
Poorly correlated
+2.21%
LUNG - STRR
23%
Poorly correlated
+0.75%
MODD - STRR
22%
Poorly correlated
+0.55%
More